Loading...
| A00001 | Pages: 165 | May 2021 | 53330 Views | | |
| Author(s) : Smita Nerkar, Monika Darandale , Onkar Sumant | Tables: 26 | Charts: 26 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Erythropoietin Drugs Market
Request Now !The erythropoietin drugs market size was valued at $9,243.12 million in 2020, and is projected to reach $14,414.59 million by 2028, registering a CAGR of 5.7% from 2021 to 2028.
Erythropoietin (EPO)/hematopoietin is a glycoprotein hormone that triggers production of red blood cells in the bone marrow through erythropoiesis. Erythropoietin drug was developed with the objective to treat anemic conditions caused from end stage renal disease (ESRD) disease treatments and dialysis procedures. Followed by ESRD anemic condition, EPO drugs have gained approvals for chemotherapy-induced anemia. After post-abbreviated new drug application (ANDA) approvals and high success rate of EPO applications for chemotherapy-induced anemia, original biopharmaceutical companies turned their attention to another form of induced anemia, namely ART-induced anemia (among HIV patients).
Get more information on this report : Request Sample Pages
Rise in prevalence of anemic conditions induced from end stage renal disease treatment, chemotherapy, and antiretroviral treatment (ART) is the primary factor that propels growth of the erythropoietin market. Hence, rise in number of treatment cycles for chemotherapy and increase in incidences of end stage renal diseases (dialysis) has increased demand for EPO. Side effects associated with EPO including arterial hypertension, iron deficiency, and influenza-like syndrome and longer duration of EPO treatment (4-6 weeks) restrain growth of the erythropoietin drugs market. In addition, rise in trends of commercialization for erythropoietin biosimilars, readily available reimbursements, favorable government regulations, and increase in level of awareness regarding benefits of EPO therapeutics boost growth of the erythropoietin drugs market.
The outbreak of COVID-19 has disrupted workflows in the health care sector across the globe. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there has also been a positive effect and surge in demand for various medical services, including erythropoietin. As erythropoietin (EPO) is a drug for anemia and can be effective against COVID-19, as per scientists at Max Planck Institute of Experimental Medicine in Göttingen. According to them, when the SARS-CoV-2 attacks brain, growth aspect of erythropoietin can mitigate serious disease development and protect people from long-term neurological impacts. Primary case studies suggest a favorable effect of erythropoietin. Currently, scientists are planning a randomized clinical trial to systematically investigate effects of treating COVID-19 using erythropoietin. It is a hormone/cytokine produced mainly by kidneys via hypoxia inducible factor-2 as its primary transcription factor and through inhibition of apoptosis of RBC precursors. However, EPO has other beneficial cytoprotective effects including anti-ischemic, regenerative, and anti-apoptotic effects in a variety of tissues including lung, kidney, cardiac muscle, nervous system, retina, pancreas, and endothelial cells. Through a special receptor; EPOR-ᵦcR, it conducts its protective effects following trauma in critically ill patients. Thus, impact of COVID-19 pandemic is expected to remain positive for key players in the erythropoietin drugs market.
Get more information on this report : Request Sample Pages
The global erythropoietin drugs market is segmented into product type, application, and region. On the basis of product type, the market is categorized into erythropoietin-alfa, erythropoietin-beta, and darbepoetin-alfa. By application, it is classified into anemia, kidney disorders, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By product type, currently, the epoetin-alfa segment dominates the global market, and is expected maintain its dominance during the forecast period, owing to high usage rate in alleviating condition of anaemia in patients with cancer and chronic renal failure. By application, the kidney disorders segment is expected to generate highest revenue during the forecast period, owing to increase in prevalence of end stage renal disease and increase in demand for dialysis.
Get more information on this report : Request Sample Pages
Asia-pacific is a promising market for growth of erythropoietin and majority of originator companies for erythropoietin are focusing on the Asia-pacific market. The region demonstrates largest share of the biosimilar industry, owing to development of biosimilars by major manufacturers in these regions. India and China are major erythropoietin biosimilar markets. The cost involved in development of biosimilars in India varies between $10 and $20 million, owing to industrial environment and government legislations. Moreover, development of biosimilars in majority of countries in Asia-pacific, such as India, do not require phase I/II studies, however, mandate phase III studies with minimum 100 patients. Hence, majority of biosimilar manufacturers in Asia-pacific can afford to launch biosimilar versions of erythropoietin at 25–40% less price than innovator products.
The key erythropoietin drugs market players profiled in the report include Amgen Inc., Johnson & Johnson, Hospira Inc., Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.
Get more information on this report : Request Sample Pages
Key Benefits For Stakeholders
Key Market Segments
By Product Type
By Application
By Region
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits
1.3.Key market segments
1.4.Research methodology
1.4.1.Primary research
1.4.2.Secondary Research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Clinical trials for EPO drug
3.3.Market share analysis, 2020
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increasing number cases: including cancer,HIV, kidney disease and anaemia
3.4.1.2.Growing trends of commercialization for erythropoietin biosimilars
3.4.1.3.Increasing level of awareness about the benefits of EPO therapeutics
3.4.2.Restraints
3.4.2.1.Unaffordability of therapeutics
3.4.2.2.Longer duration of treatments
3.4.2.3.Adverse amount of side effects
3.4.3.Opportunities
3.4.3.1.Commercialization of Darbepoetin alfa biosimilar
3.4.3.2.Achieving Economies of scale across developed region with biosimilar version of EPO
3.5.Impact of Covid-19 on Erythropoietin Drug Market
CHAPTER 4:GLOBAL ERYTHROPOIETIN MARKET BY PRODUCTS
4.1.Epoetin-alfa
4.1.1.Key market trends and opportunities
4.1.2.Market size and forecast
4.1.3.Market analysis, by country
4.2.Epoetin-beta
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Darbepoetin-alfa
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Other
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
CHAPTER 5:GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS
5.1.Hematology
5.1.1.Market size and forecast
5.1.2.Market analysis, by country
5.2.Kidney Disorders (ESRD and Dialysis)
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Cancer
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Others
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
CHAPTER 6:GLOBAL ERYTHROPOIETIN MARKET BY GEOGRAPHY
6.1.North America
6.1.1.Key market trends & opportunities
6.1.2.Market size and forecast
6.2.Europe
6.2.1.Key market trends & opportunities
6.2.2.Market size and forecast
6.3.Asia-Pacific
6.3.1.Key market trends & opportunities
6.3.2.Market size and forecast
6.4.LAMEA
6.4.1.Key market trends & opportunities
6.4.2.Market size and forecast
CHAPTER 7:COMPANY PROFILES
7.1.AMGEN INC.
7.1.1.Company overview
7.1.2.Amgen Inc. snapshot
7.1.3.Operating Business Segment
7.1.4.Financial performance
7.2.JOHNSON AND JOHNSON
7.2.1.Company overview
7.2.2.Johnson & Johnson snapshot
7.2.3.Operating Business Segment overview
7.2.4.Financial performance
7.3.ROCHE DIAGNOSTICS
7.3.1.Company overview
7.3.2.Roche Diagnostics snapshot
7.3.3.Operating Business Segment Overview
7.3.4.Financial performance
7.4.HOSPIRA INC.
7.4.1.Company overview
7.4.2.Hospira Inc. snapshot
7.4.3.Operating business segment
7.4.4.Financial performance
7.4.5.Key Strategies move & development
7.5.LG LIFE SCIENCES LTD.
7.5.1.Company overview
7.5.2.LG Life Sciences Ltd. snapshot
7.5.3.Operating Business segment overview
7.5.4.Financial performance
7.6.BIOCON
7.6.1.Company overview
7.6.2.Biocon snapshot
7.6.3.Operating Business Segment Overview
7.6.4.Financial performance
7.6.5.Key Strategies move and development
7.7.INTAS PHARMACEUTICALS
7.7.1.Company overview
7.7.2.Intas Pharmaceuticals snapshot
7.7.3.Operating Business Segment Overview
7.7.4.Financial performance
7.8.TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.8.1.Company overview
7.8.2.Teva Pharmaceutical Industries Ltd. snapshot
7.8.3.Operating business segment overview
7.8.4.Financial performance
7.9.RANBAXY LABORATORIES LTD.
7.9.1.Company overview
7.9.2.Ranbaxy Laboratories Ltd. snapshot
7.9.3.Operating business segment overview
7.9.4.Financial performance
7.10.CELLTRION, INC
7.10.1.Company overview
7.10.2.Celltrion, Inc. snapshot
7.10.3.Financial performance
LIST OF TABLES
TABLE 01.CLINICAL TRIALS OF ERYTHROPOEITIN FOR NEURAL DISEASES AND WOUND HEALING
TABLE 02.GLOBAL ERYTHROPOIETIN DRUG MARKET BY PRODUCT TYPES, 2020-2028($MILLION)
TABLE 03.GLOBAL ERYTHROPOIETIN ALFA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 04.GLOBAL ERYTHROPOIETIN BETA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 05.GLOBAL DARBEPOETIN ALFA DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 06.GLOBAL OTHER DRUGS MARKET BY GEOGRAPHY, 2020-2028($MILLION)
TABLE 07.GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS, 2020-2028($MILLION)
TABLE 08.GLOBAL HEMATOLOGY APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 09.GLOBAL ESRD AND DIALYSIS INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 10.GLOBAL CANCER APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 11.GLOBAL OTHERS APPLICATION MARKET BY GEOGRAPHY, 2020-2028, $MILLION
TABLE 12.GLOBAL ERYTHROPOETIN MARKET BY GEOGRAPHY, 2020 – 2020 ($MILLION)
TABLE 13.NORTH AMERICA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 15.EUROPE ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 17.ASIA-PACIFIC ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 18.LAMEA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2020 – 2020 ($MILLION)
TABLE 19.AMGEN INC. SNAPSHOT
TABLE 20.AMGEN INC. OPERATING BUSINESS SEGMENT
TABLE 21.JOHNSON & JOHNSON SNAPSHOT
TABLE 22.JOHNSON AND JOHNSON OPERATING SEGEMENTS
TABLE 23.ROCHE DIAGNOSTICS SNAPSHOT
TABLE 24.ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 25.HOSPIRA INC. SNAPSHOT
TABLE 26.HOSPIRA INC. OPERATING SEGEMENTS
TABLE 27.LG LIFE SCIENCES LTD. DIAGNOSTICS SNAPSHOT
TABLE 28.LG LIFE SCIENCES LTD. DIAGNOSTICS OPERATING SEGEMENTS
TABLE 29.BIOCON SNAPSHOT
TABLE 30.BIOCON OPERATING SEGEMENTS
TABLE 31.INTAS PHARMACEUTICALS SNAPSHOT
TABLE 32.INTAS PHARMACEUTICALS OPERATING SEGEMENTS
TABLE 33.TEVA PHARMACEUTICAL INDUSTRIES LTD. SNAPSHOT
TABLE 34.TEVA PHARMACEUTICAL INDUSTRIES LTD. OPERATING SEGEMENTS
TABLE 35.RANBAXY LABORATORIES LTD. SNAPSHOT
TABLE 36.CELLTRION, INC. SNAPSHOT
LIST OF FIGURES
FIGURE 01.GLOBAL ERYTHROPOIETIN (EPO) DRUGS MARKET DEFINITION
FIGURE 02.MARKET SHARE ANALYSIS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2020)
FIGURE 03.FINANCIAL REVENUE OF AMGEN INC. BY GEOGRAPHY (2020)
FIGURE 04.FINANCIAL REVENUE OF AMGEN INC. BY PRODUCT PORTFOLIO (2020)
FIGURE 05.SWOT ANALYSIS OF AMGEN INC.
FIGURE 06.FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2020)
FIGURE 07.FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS(2020)
FIGURE 08.SWOT ANALYSIS OF JOHNSON & JOHNSON
FIGURE 09.FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2020)
FIGURE 10.FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2020)
FIGURE 11.SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIGURE 12.FINANCIAL REVENUE OF HOSPIRA INC. BY GEOGRAPHY (2020)
FIGURE 13.FINANCIAL REVENUE OF HOSPIRA INC. BY BUSINESS UNITS (2020)
FIGURE 14.SWOT ANALYSIS OF HOSPIRA INC.
FIGURE 15.NET REVENUE GENERATION (2011-2020)
FIGURE 16.SWOT ANALYSIS OF LG LIFE SCIENCES LTD.
FIGURE 17.REVENUE GENERATED BY BUSINESS UNITS (2020)
FIGURE 18.SWOT ANALYSIS OF BIOCON
FIGURE 19.SWOT ANALYSIS OF INTAS PHARMACEUTICALS
FIGURE 20.NET REVENUE GENERATION BY GEOGRAPHY (2020)
FIGURE 21.NET REVENUE GENERATION BY BUSINESSES (2020)
FIGURE 22.SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
FIGURE 23.KEY FINANCIALS OF RANBAXY LABORATORIES LIMITED BY GEOGRAPHY (2014)
FIGURE 24.SWOT ANALYSIS OF RANBAXY LABORATORIES LTD.
FIGURE 25.NET PROFIT DURING 2011-2020
FIGURE 26.SWOT ANALYSIS OF CELLTRION, INC.
This section provides opinions of the top level CXOs in the erythropoietin drugs market. According to the CXOs, erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia; a common side effect that occurs due to chemotherapy for ESRD, cancer, and HIV. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin-alfa, epoetin-beta, darbepoetin-alfa, epoetin-omega, and epoetin-delta.
As per CXOs, number of treatment cycles for chemotherapy and increase in number of cases of cancer, HIV, kidney disease, and anemia has increased demand for EPO. Moreover, favorable reimbursement and regulations for EPO treatment provide recordable growth for the erythropoietin drugs market. However, side effects associated with EPO including arterial hypertension, iron deficiency, and influenza-like syndrome and longer duration of EPO treatment (4-6 weeks) are expected to restrain the market growth. Moreover, commercialization of highly potent version of erythropoietin-alfa has provided high growth opportunities for the erythropoietin drugs market.
CXOs further added that erythropoietin-alfa segment is anticipated to grow with the highest revenue throughout the forecast period, owing to increase in sales of Epogen. In addition, kidney disorders segment accounted for a major share in 2020, and is expected to exhibit a prominent growth rate during the forecast period, owing to increase in cases of patients. Moreover, North America dominates the global erythropoietin drugs market, owing to the presence of several approved and commercialized erythropoietin biosimilars. Asia-Pacific and LAMEA offer promising growth opportunities for erythropoietin manufacturers as these regions are less explored for erythropoietin drugs as compared to North America and Europe.
A. The total market value of Erythropoietin Drugs Market is $9,243.12 million in 2020.
A. The forcast period for ErythropoietinHeparin market is 2021 to 2028
A. The market value of Erythropoietinmarket in 2021 is $9,808.80 million.
A. The base year is 2020 in Erythropoietin Drugs Market
A. Top companies such as Amgen Inc., Biocon, Celltrion, Inc., Intas Pharmaceuticals, Johnson & Johnso, LG Life Sciences Ltd., Pfizer (Hospira), Ranbaxy Laboratories Ltd., Roche, and Teva Pharmaceutical Industries Ltd held a high market position in 2020.
A. kidney disorders (ESRD and Dialysis) segment accounted for a major share in 2020 and is expected to exhibit a prominent growth rate during the forecast period, owing to increase in cases of patients with kidney disease.
A. Increase in number of treatment cycles for the chemotherapy and increasing number cases: including cancer, HIV, kidney disease and anaemia has increased the demand for EPO. Moreover, favorable reimbursement and regulations for EPO treatment provide recordable growth for the erythropoietin drugs market.
A. North America accounted for the largest share of the global erythropoietin drugs market in 2020, and is expected to remain dominant throughout the forecast period. This was attributed to the presence of several approved and commercialized erythropoietin biosimilars.
A. Erythropoietin/hematopoietin is a glycoprotein hormone that triggers the production of red blood cells in the bone marrow through erythropoiesis.
A. The erythropoietin drug was developed with the objective of treating anemic conditions caused from ESRD disease treatments and dialysis procedures.
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
